Senate Chooses Baucus Approach To Comp. Effectiveness, With Tweaks
This article was originally published in The Gray Sheet
The Senate health reform 1bill up for floor debate this week essentially retains the industry-supported Baucus/Conrad approach to a national comparative effectiveness research infrastructure, but includes some subtle changes of note
You may also be interested in...
Senate health care reform 1legislation up for floor debate this week contains both positives and negatives for makers of in vitro diagnostics and for testing labs, but would reduce expected Medicare payment cuts in the sector compared to the package approved by the Senate Finance Committee last month
Consensus on Capitol Hill is centering on a total tax to the device industry of $20 billion over 10 years to help cover health care reform spending, but the structure of the tax and how it will be allocated remain up in the air
A distinct consensus is emerging in Washington that comparative effectiveness research needs to be done in a way that does not threaten the progress of personalized medicine